Antimicrobial Synthetic Bone Grafts

Bone Infection Clinical Trial

Official title:

The Use of Antimicrobial Synthetic Bone Grafts in the Treatment of Bone Infection

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03945864
• Other study ID #: 2019-2491
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: June 1, 2019
• Est. completion date: August 15, 2021

Study information

• Verified date: July 2022
• Source: Eskisehir Osmangazi University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This project aims to produce synthetic bone tissue graft that supports bone regeneration and combats infection simultaneously, according to industry standards and regulations. This original and high value added biomaterial "silver doped calcium phosphate based synthetic bone tissue " will be used in clinical trials in patients with osteomyelitis and implant-related infections for the treatment.

Chronic bone infections are one of the most important problems in orthopedic surgery and are not just a problem of developed societies. When open fracture cases, which may get infected in 1-50%, implant-related infections and diabetic foot ulcer cases are taken into consideration, osteomyelitis will be seen as a very common problem all over the world. Multiple surgeries, long-term use of antibiotics and the high costs affects all societies. The use of synthetic bone grafts is growing faster than the natural bone grafts in the world. USA has spent 246 million US dollars for the use of synthetic bone graft in 2010. For the treatment of bone infections antibiotic impregnated synthetic bone grafts with different characteristics are used. Although these antibiotic impregnated synthetic bone grafts are superior compared to antibiotic bone cement with the implementation of different antibiotics and to be absorbable but they cannot show optimum benefit because the release of antibiotics is not due to host matrix degradation but diffusion control. The other issue to be considered as this regard that the development of microbial resistance to these antibiotics which is also a serious problem. Innovative synthetic bone graft with better contribution of the needs of mechanical properties, depending on the applied bone region, optimized antimicrobial activity and bone tissue regeneration are needed.

In this study, it will be determined whether this silver ion -doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids that may occur in chronic bone infection during disease process or after surgical debridement, also has the capacity to treat the infection in the bone will be used in 12 patients who had been diagnosed as chronic osteomyelitis to see if it cause any unwanted side effect in normal usage conditions and generates unacceptable risks. Clinical, laboratory and radiological investigations will be used to demonstrate the healing of the infections and the cavities in the bone. Blood and urine levels of silver will be detected from patients.

Antimicrobial activity of silver is well-known. The effectiveness of the silver and potential toxicity is related to the dose of silver and application form. In orthopedics, the use of silver is mostly limited to elemental silver coating of metal implants. There is no biotechnologic approach manufactured silver ion -doped calcium phosphate -based synthetic bone graft in the health sector yet. Ionic silver has advantages such as low toxicity, no tolerance of silver against bacteria, and strong antibacterial activity. The trapping of silver ions in the calcium phosphate based ceramic structure overcomes the other systems with its controlled release and its ability to be effective at minimum doses. The project is an original work since it will contribute to bone regeneration while at the same time removing the infection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: August 15, 2021
• Est. primary completion date: September 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Patients with chronic osteomyelitis, infected non-union or implant-associated infection with an indication for artificial bone grafting who read and accept the Informed consent.

• Male and female patients older than 18 years

• Patients without heart, lung, renal or hepatic failure, epilepsy, cerebrovascular attack or ischemia

• Patients who are not allergic to antibiotics

• Patients with additional immunosuppression such as malignancy, diabetes mellitus, poly travma and open fractures

• Patients using oral or parenteral corticosteroids, methotrexate, cyclosporine or other immunosuppressive drugs

Exclusion Criteria:

• Patients who have not accepted the method.

• Patients outside the working age range

• Pregnant women

• Patients with heart, lung, renal, hepatic failure, epilepsy, cerebrovascular attack or ischemia

• Patients with allergy to antibiotics

• Patients with another silvery implant in the body like a silver-coated implant

• Patients with a history of known allergies or hypersensitivity to silver

Related Conditions & MeSH terms

• Bone Graft Infection
• Bone Infection
• Communicable Diseases
• Infections

Intervention

Device:
• antimicrobial synthetic bone graft
It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
• parentaral antimicrobials and pure bone grafts
Historical data of the department will be used for comparison of the results

Locations

Country	Name	City	State
Turkey	Eskisehir Osmangazi University Hospital	Eskisehir

Sponsors (1)

Lead Sponsor	Collaborator
Eskisehir Osmangazi University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bony healing of the cavities in the bone	Number of Participants with bony healing of the cavities in the bone by x-ray	12 months